Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1220 - A liquid biopsy gene panel for pancreatic cancer detection (30P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Kikuya Kato

Citation

Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653

Authors

K. Kato1, K. Ohkawa2, R. Takada2, H. Uehara2, Y. Kukita1, K. Katayama2

Author affiliations

  • 1 Graduate School Of Biological Sciences, Nara Institute of Science and Technology, 630-0101 - Ikoma/JP
  • 2 Department Of Hepatobiliary And Pancreatic Oncology, Osaka International Cancer Institute, Osaka/JP
More

Resources

Abstract 1220

Background

Since surgical resection of localized pancreatic cancer improves overall survival, its early detection would have substantial benefits. Circulating tumor DNA, which is drawing attention as a part of liquid biopsy, might be useful for pancreatic cancer detection. Although KRAS mutations appear in the majority of pancreatic cancer cases, screening for other gene mutations in plasma may improve detection.

Methods

We used the non-overlapping integrated read sequencing system (NOIR-SS), a next-generation sequencing method with improved accuracy, to sequence a panel of pancreatic cancer-related genes including KRAS, TP53, SMAD4, CTNNB1, CDKN2A, GNAS, HRAS, and NRAS (comprising 2.8 kb of genomic DNA) in plasma DNA. NOIR-SS eliminates PCR/sequencing errors by building a consensus sequence from reads with the same molecular barcode.

Results

Of 77 patients with localized pancreatic cancer, 9 (11.7%) and 16 (20.8%) patients were variant-positive for KRAS and any of the aforementioned genes. Of 67 patients with metastatic pancreatic cancer, 28 (52.2%) and 35 (41.8%) patients were variant-positive for KRAS and any of the aforementioned genes. No variant was detected in 12 healthy individuals. Of 20 patients with intra-ductal papillary mucous neoplasms (IPMN), only one mutation in TP53 was found.

Conclusions

The sequencing system removed artifacts during the assay process, and achieved near complete elimination of variant detection in control populations, namely in healthy individuals and IPMN. Sequencing of pancreatic cancer-related genes revealed an approximately 10% increase in detection rate from that with KRAS alone, thus demonstrating the merit of analyzing multiple genes.

Clinical trial identification

Legal entity responsible for the study

Osaka International Cancer Institute

Funding

None

Disclosure

K. Kato: Employment (part time): DNA Chip Research Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings